查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438147

至 2030 年磺胺类药物市场预测：按类型、配方、给药途径、应用、最终用户和地区进行的全球分析

Sulphonamides Market Forecasts to 2030 - Global Analysis By Type (Sulfamethoxazole, Sulfadiazine, Sulfacetamide, Sulfasalazine, Sulfadoxine and Other Types), Formulation, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球磺胺类药物市场规模为 1.1521 亿美元，预计 2030 年将达到 1.8621 亿美元，预测期内复合年增长率为 7.1%。

磺胺类药物是一种合成抗生素，常用于治疗细菌感染疾病。它作为细菌叶酸合成的竞争性抑制剂，抑制必要的代谢过程并抑制细菌生长。全身磺胺类药物类药物可口服或肠胃外给药，用于治疗多种感染疾病，局部製剂可解决局部问题。磺胺类药物的多功能性在人类医学和兽医学中都有应用。

根据 NCBI 统计，美国每年报告超过 1400 万例蜂窝组织炎病例，使其成为最常见的细菌性皮肤感染疾病之一。蜂窝组织炎每年导致 65 万人住院治疗，门诊医疗费用约 37 亿美元。

感染疾病增加

全球感染疾病的增加增加了对磺酰胺类磺胺类药物的磺胺类药物，因为它们可以有效治疗细菌感染疾病。由于迫切需要有效治疗方法各种细菌性疾病，製药业预计将增加这些药物的使用。这一趋势在人口不断增长和医疗基础设施发达的地区尤为明显，加强了磺胺类药物在更广泛范围内应对感染疾病持续挑战的作用。

人们越来越担心副作用

患者和医疗专业人员都对皮疹和过敏反应等副作用表示担忧，阻碍了该药物的广泛普及。患者和医疗保健专业人员对潜在的不利事件表示担忧，从而影响了该药物的整体普及。副作用的风险可能会降低患者的依从性，并使医生不愿意开立磺胺类药物。这种担忧可能会导致人们对替代抗生素和治疗方案的偏好发生转变，从而阻碍市场成长。

人口成长和医疗基础设施发展

随着人口的增长，细菌感染疾病的盛行率增加，增加了对有效治疗方法的需求。特别是在发展中地区，医疗设施的改善改善了磺胺类药物的取得并增加了使用量。加强医疗基础设施将有助于更好的诊断和治疗，促进磺胺类药物在各种感染疾病管理中的应用。人口增长和医疗能力提高的动态协同效应使磺胺类药物成为满足快速发展的社会日益增长的医疗需求的重要组成部分。

活动频谱有限

在需要频谱覆盖的情况下，替代抗生素是首选。寻求综合治疗的医生可以选择活性更广泛的抗生素。由于其作用范围有限，磺胺类药物胺类抗生素可能被排除在治疗方法之外，从而限制了其使用和市场占有率。这一限制阻碍了磺胺类药物的多功能性，并且在更广泛的抗菌频谱被认为对于有效的治疗性介入至关重要的情况下提出了挑战。

COVID-19 的影响

COVID-19 的爆发扰乱了供应链并导致抗菌药物的需求波动，从而影响了磺胺类药物市场。医疗重点转向控制大流行，影响了日常护理。製造和通路的中断以及经济的不确定性进一步影响了磺胺类药物市场。然而，由于某些磺胺类药物对于治疗细菌感染疾病至关重要，我们预期市场将保持需求，同时适应更广泛的全球医疗保健领域持续存在的挑战。

锭剂市场预计将在预测期内成为最大的市场

锭剂市场预计将出现良好的成长。磺胺类药物锭剂抗生素的一种，在治疗细菌感染疾病方面发挥重要作用。这些锭剂含有磺基化合物，透过抑制叶酸合成来抑制细菌生长。磺胺类药物锭剂通常用于治疗尿道感染、呼吸道感染疾病和其他细菌性疾病，它提供了一种有针对性的治疗方法。正在进行研究以改进配方并克服局限性，以确保磺胺类药物锭剂对多种细菌感染疾病保持有效。

预计抗生素领域在预测期内复合年增长率最高

预计抗菌产业在预测期内将经历最高的复合年增长率。作为抗菌剂，磺胺类药物在对抗细菌感染疾病方面发挥重要作用。磺胺类药物因其抑菌特性而被广泛使用，可抑制细菌叶酸合成并抑制 DNA 和 RNA 的产生。这使其能够有效对抗多种细菌病原体。磺胺类药物的抗菌作用延伸至感染疾病、泌尿系统和感染疾病。磺胺类药物作为抗菌疗法仍然具有至关重要的作用，并为世界对抗细菌性疾病的武器库做出了重大贡献。

占比最高的地区

由于北美地区医疗基础设施发达、研发实力雄厚、感染疾病率高，预计在预测期内将占最高份额。该地区拥有完善的製药业，促进了磺胺类药物製剂的创新。此外，由于医药产品的进步和积极主动的感染疾病管理方法，北美仍然是一个强劲的市场。

复合年增长率最高的地区：

由于医疗基础设施不断增加、感染疾病流行和人口快速增长等因素，亚太地区磺胺类药物市场正在经历显着增长。该地区製药业的扩张和政府对抗感染疾病的努力正在推动市场需求。亚太国家越来越多地采用磺胺类药物来治疗细菌感染疾病，重点是改善医疗保健的可近性。此外，持续的研发活动也促进了市场的活力，使亚太地区成为磺胺类药物市场的主要参与者。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球磺胺类药物市场：依类型

  • 磺胺甲噁唑
  • 磺胺嘧啶
  • 磺胺乙酰胺
  • 柳氮磺吡啶
  • 磺胺多辛
  • 其他的

第六章全球磺胺类药物市场：依配方分类

  • 锭剂
  • 液体
  • 粉末
  • 其他的

第七章全球磺胺类药物市场：依给药途径分类

  • 口服
  • 胃肠外的
  • 局部的

第八章全球磺胺类药物市场：依应用分类

  • 抗菌的
  • 抗真菌剂
  • 抗疟疾药
  • 利尿剂
  • 抗病毒药
  • 其他的

第九章全球磺胺类药物市场：依最终用户分类

  • 製药
  • 兽医
  • 农业
  • 化妆品
  • 食品与饮品
  • 其他的

第十章全球磺胺类药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Viatris Inc
  • Pfizer Inc
  • AA Pharma Inc
  • GlaxoSmithKline PLC
  • Azurity Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Valeo Pharma
  • Novartis Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd
  • Akorn Operating Company LLC
  • Sanofi SA
  • Roche Holding AG
  • Merck & Co.
  • Bayer AG
  • Johnson & Johnson
  • Abbott Laboratories
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
Product Code: SMRC25116

According to Stratistics MRC, the Global Sulphonamides Market is accounted for $115.21 million in 2023 and is expected to reach $186.21 million by 2030 growing at a CAGR of 7.1% during the forecast period. Sulphonamides are a class of synthetic antimicrobial drugs commonly used to treat bacterial infections. Acting as competitive inhibitors of folic acid synthesis in bacteria, they hinder essential metabolic processes, suppressing bacterial growth. Systemic sulphonamides are administered orally or parenterally for widespread infections, while topical formulations address localized issues. Their versatility extends to applications in both human and veterinary medicine.

According to NCBI, over 14 million cases of cellulitis are reported each year in the U.S., making it one of the most frequent bacterial skin infections. It is responsible for 650,000 hospital admissions per year and ambulatory care expenses of about USD 3.7 billion.

Market Dynamics:

Driver:

Increasing prevalence of infectious diseases

The mounting incidence of infectious diseases globally enhances the need for sulphonamides since these antimicrobial medicines successfully treat bacterial infections. Given the pressing need for efficient therapies against a variety of bacterial diseases, the pharmaceutical industry expects to see an increase in the use of these medications. This trend is particularly pronounced in regions with expanding populations and improving healthcare infrastructures, reinforcing sulphonamides' role in addressing the persistent challenge of infectious diseases on a broader scale.

Restraint:

Rising concerns about side effects

Concerns regarding possible side effects like rashes and allergic reactions are voiced by both patients and medical professionals, which hinders the drug's general uptake. Patients and healthcare professionals express apprehensions about potential adverse events, impacting the drug's overall adoption. The perceived risk of side effects can lead to a decline in patient compliance and reluctance among physicians to prescribe sulphonamides. This apprehension may divert preference towards alternative antibiotics or treatment options, hindering the market growth.

Opportunity:

Growing population and healthcare infrastructure

With a growing populace, the incidence of bacterial infections rises, fostering increased demand for effective treatments. Improved healthcare facilities, especially in developing regions, enhance access to sulphonamides, amplifying their usage. The strengthened healthcare infrastructure facilitates better diagnosis and treatment, promoting the adoption of sulphonamides in managing various infectious diseases. This dynamic synergy between population growth and enhanced healthcare capabilities positions sulphonamides as essential components in addressing the escalating healthcare needs of burgeoning societies.

Threat:

Limited spectrum of activity

In scenarios requiring broad-spectrum coverage, alternative antibiotics are the most favoured. Physicians, aiming for comprehensive treatments, may opt for antibiotics with a broader range of activity. The constrained scope of sulphonamides may result in their exclusion from treatment regimens, limiting their application and market share. This limitation hinders the versatility of sulphonamides, posing a challenge in situations where a more expansive antibacterial spectrum is deemed crucial for effective therapeutic interventions.

Covid-19 Impact

The covid-19 pandemic has influenced the sulphonamides market by disrupting supply chains, causing fluctuations in demand for antimicrobial agents. Healthcare priorities shifted towards managing the pandemic, impacting routine treatments. Disruptions in manufacturing and distribution channels, along with economic uncertainties, further affected the sulphonamides market. However, the essential nature of some sulphonamides in treating bacterial infections likely sustained demand, with the market adapting to ongoing challenges in the broader context of the global healthcare landscape.

The tablets segment is expected to be the largest during the forecast period

The tablets segment is estimated to have a lucrative growth. Sulphonamides tablets, a class of antimicrobial drugs, play a crucial role in treating bacterial infections. These tablets contain sulfa-based compounds that inhibit bacterial growth by interfering with folate synthesis. Commonly prescribed for urinary tract infections, respiratory tract infections, and other bacterial ailments, sulphonamide tablets offer a targeted therapeutic approach. Ongoing research aims to enhance formulations and overcome limitations, ensuring sulphonamide tablets continue to be effective and relevant in addressing a range of bacterial infections.

The antibacterial segment is expected to have the highest CAGR during the forecast period

The antibacterial segment is anticipated to witness the highest CAGR growth during the forecast period. Sulphonamides, as antibacterial agents, play a crucial role in combating bacterial infections. Widely utilized for their bacteriostatic properties, sulphonamides inhibit bacterial folate synthesis, impeding DNA and RNA production. This makes them effective against a range of bacterial pathogens. Their antibacterial application extends to respiratory, urinary, and skin infections. Sulphonamides continue to be pivotal in antibacterial therapeutics, contributing significantly to the global arsenal against bacterial diseases.

Region with largest share:

North America is projected to have the highest share over the forecast period, owing to its advanced healthcare infrastructure, robust research and development initiatives, and a high prevalence of infectious diseases. The region's well-established pharmaceutical sector fosters innovation in sulphonamide formulations. Further, North America remains a prominent market, with pharmaceutical advancements and a proactive approach toward infectious disease management fueling its continued prominence.

Region with highest CAGR:

The sulphonamides market in Asia Pacific is experiencing notable growth due to factors such as increasing healthcare infrastructure, rising prevalence of infectious diseases, and a burgeoning population. The region's expanding pharmaceutical industry, coupled with government initiatives to combat infections, propels market demand. With a focus on improving healthcare accessibility, countries in Asia Pacific are witnessing higher adoption of sulphonamides for treating bacterial infections. Additionally, ongoing research and development activities contribute to the market's dynamism, positioning Asia Pacific as a key player in the sulphonamides market.

Key players in the market

Some of the key players profiled in the Sulphonamides Market include Viatris Inc, Pfizer Inc, AA Pharma Inc, GlaxoSmithKline PLC, Azurity Pharmaceuticals, Teva Pharmaceutical Industries Limited, Valeo Pharma, Novartis Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Akorn Operating Company LLC, Sanofi S.A., Roche Holding AG, Merck & Co., Bayer AG, Johnson & Johnson, Abbott Laboratories, Bristol Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC and Boehringer Ingelheim International GmbH.

Key Developments:

In August 2022, Valeo Pharma Inc. and Novartis Pharmaceuticals Canada Inc., a subsidiary of Novartis AG, signed a supply and distribution agreement for SIMBRINZA in Canada. Brinzolamide is a carbonic anhydrase inhibitor and sulfonamide with a specific affinity for carbonic anhydrase II. This move ensured a broader reach of its products in the global market.

In July 2022, Azurity Pharmaceuticals Inc. received approval from the US FDA for ZONISADE (zonisamide oral suspension). Zonisamide is a sulfonamide antiepileptic drug.

Types Covered:

  • Sulfamethoxazole
  • Sulfadiazine
  • Sulfacetamide
  • Sulfasalazine
  • Sulfadoxine
  • Other Types

Formulations Covered:

  • Tablets
  • Liquid
  • Powder
  • Other Formulations

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Topical

Applications Covered:

  • Antibacterial
  • Antifungal
  • Antimalarial
  • Diuretic
  • Antiviral
  • Other Applications

End Users Covered:

  • Pharmaceuticals
  • Veterinary Medicine
  • Agriculture
  • Cosmetics
  • Food & Beverage
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Sulphonamides Market, By Type

  • 5.1 Introduction
  • 5.2 Sulfamethoxazole
  • 5.3 Sulfadiazine
  • 5.4 Sulfacetamide
  • 5.5 Sulfasalazine
  • 5.6 Sulfadoxine
  • 5.7 Other Types

6 Global Sulphonamides Market, By Formulation

  • 6.1 Introduction
  • 6.2 Tablets
  • 6.3 Liquid
  • 6.4 Powder
  • 6.5 Other Formulations

7 Global Sulphonamides Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Topical

8 Global Sulphonamides Market, By Application

  • 8.1 Introduction
  • 8.2 Antibacterial
  • 8.3 Antifungal
  • 8.4 Antimalarial
  • 8.5 Diuretic
  • 8.6 Antiviral
  • 8.7 Other Applications

9 Global Sulphonamides Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceuticals
  • 9.3 Veterinary Medicine
  • 9.4 Agriculture
  • 9.5 Cosmetics
  • 9.6 Food & Beverage
  • 9.7 Other End Users

10 Global Sulphonamides Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Viatris Inc
  • 12.2 Pfizer Inc
  • 12.3 AA Pharma Inc
  • 12.4 GlaxoSmithKline PLC
  • 12.5 Azurity Pharmaceuticals
  • 12.6 Teva Pharmaceutical Industries Limited
  • 12.7 Valeo Pharma
  • 12.8 Novartis Pharmaceuticals
  • 12.9 Sun Pharmaceutical Industries Ltd
  • 12.10 Akorn Operating Company LLC
  • 12.11 Sanofi S.A.
  • 12.12 Roche Holding AG
  • 12.13 Merck & Co.
  • 12.14 Bayer AG
  • 12.15 Johnson & Johnson
  • 12.16 Abbott Laboratories
  • 12.17 Bristol Myers Squibb Company
  • 12.18 Eli Lilly and Company
  • 12.19 AstraZeneca PLC
  • 12.20 Boehringer Ingelheim International GmbH

List of Tables

  • Table 1 Global Sulphonamides Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Sulphonamides Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Sulphonamides Market Outlook, By Sulfamethoxazole (2021-2030) ($MN)
  • Table 4 Global Sulphonamides Market Outlook, By Sulfadiazine (2021-2030) ($MN)
  • Table 5 Global Sulphonamides Market Outlook, By Sulfacetamide (2021-2030) ($MN)
  • Table 6 Global Sulphonamides Market Outlook, By Sulfasalazine (2021-2030) ($MN)
  • Table 7 Global Sulphonamides Market Outlook, By Sulfadoxine (2021-2030) ($MN)
  • Table 8 Global Sulphonamides Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 9 Global Sulphonamides Market Outlook, By Formulation (2021-2030) ($MN)
  • Table 10 Global Sulphonamides Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 11 Global Sulphonamides Market Outlook, By Liquid (2021-2030) ($MN)
  • Table 12 Global Sulphonamides Market Outlook, By Powder (2021-2030) ($MN)
  • Table 13 Global Sulphonamides Market Outlook, By Other Formulations (2021-2030) ($MN)
  • Table 14 Global Sulphonamides Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 15 Global Sulphonamides Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Sulphonamides Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 17 Global Sulphonamides Market Outlook, By Topical (2021-2030) ($MN)
  • Table 18 Global Sulphonamides Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 Global Sulphonamides Market Outlook, By Antibacterial (2021-2030) ($MN)
  • Table 20 Global Sulphonamides Market Outlook, By Antifungal (2021-2030) ($MN)
  • Table 21 Global Sulphonamides Market Outlook, By Antimalarial (2021-2030) ($MN)
  • Table 22 Global Sulphonamides Market Outlook, By Diuretic (2021-2030) ($MN)
  • Table 23 Global Sulphonamides Market Outlook, By Antiviral (2021-2030) ($MN)
  • Table 24 Global Sulphonamides Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Sulphonamides Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Sulphonamides Market Outlook, By Pharmaceuticals (2021-2030) ($MN)
  • Table 27 Global Sulphonamides Market Outlook, By Veterinary Medicine (2021-2030) ($MN)
  • Table 28 Global Sulphonamides Market Outlook, By Agriculture (2021-2030) ($MN)
  • Table 29 Global Sulphonamides Market Outlook, By Cosmetics (2021-2030) ($MN)
  • Table 30 Global Sulphonamides Market Outlook, By Food & Beverage (2021-2030) ($MN)
  • Table 31 Global Sulphonamides Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.